Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...

April 03, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group ... "We are pleased with the progress across our Alzheimer’s portfolio as we move ahead with a Phase III trontinemab ...

Roche’s Genentech unit has bought California biotech ... Jecure has a preclinical portfolio of NLRP-3 class drugs used to treat inflammatory and autoimmune disorders such as NASH, liver fibrosis ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

Genentech announced that new data were presented at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria. Highlights included presentations from the ...

Now it is kowtowing to the president's anti-DEI stand. Genentech Inc. is retreating from its broad, billion-dollar DEI goals amid President Donald Trump's continuing push against government and ...

About Genentech in neuroscience Neuroscience is a major focus of research and development at Genentech and Roche. Our goal is to pursue groundbreaking science to develop new treatments that help ...

(RTTNews) - Genentech, a Roche Group member (RHHBY.OB), Thursday presented new findings at the AD/PD 2025 International Conference in Vienna, highlighting advancements in Alzheimer's and Parkinson ...

M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development. "These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow ...

--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial comparing a high dose of Ocrevus ® (ocrelizumab ...